Get the Weekly Intelligence Brief — top committee picks every Sunday.

PEN vs RARE

Penumbra, Inc. vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
PEN
Penumbra, Inc.
67
Buy
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
MetricPENRARE
AI Score 67 56
Price $326.07 $26.96
P/E Ratio 79.78× -4.62×
ROE 12.4% 718.8%
Revenue Growth YoY
Gross Margin 67.8% 83.1%
Debt / Equity 0.14× -4.13×
Dividend Yield 0.0% 0.0%
RSI (14) 79.6 54.3
Beta 0.701 0.313
Expected Upside +6.3%

AI Committee View

Current Innellis committee reasoning for PEN versus RARE.
PEN leads by 11 points.

PEN scores 67/100 (Buy) versus RARE at 56/100 (Watch).

PEN Committee View
80% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • 2 consecutive earnings misses -- execution concerns — Growth
  • RSI at 80 is in overbought territory — Technical
RARE Committee View
50% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
  • Bollinger bandwidth of 27.5% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
PEN Full Analysis RARE Full Analysis